News

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...
Moderna is set to receive $176 million in federal funding to develop a human vaccine against bird flu following outbreaks of the virus in dairy cows across several states, the Department of Health ...
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
The U.S. Centers for Disease Control and Prevention ended its emergency response for bird flu as the outbreak that sickened ...
Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...
Moderna said it plans to explore alternatives for late-stage development and manufacturing of the vaccine. Bird flu has been circulating worldwide since the 1990 and was first detected in American ...
Topline. Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U ...
Summary. Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential.
How a bird flu pandemic could emerge 06:21. The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses ...
The Trump administration has delivered its latest blow to vaccines, canceling a nearly $600-million contract to the drugmaker Moderna that was intended to develop a shot for humans against bird flu.
A veterinarian vaccinates an Egyptian vulture against avian influenza at the Mulhouse zoo, eastern France, in 2020. Moderna had been developing a vaccine to combat an outbreak of bird flu in dairy ...
Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor. May 23, 2024 10:15 AM ET Moderna, Inc. (MRNA) Stock PFE, PFE:CA, BNTX, MRNA 78 Comments 1 Like. Edmund Ingham.